| Autor: |
Ord, Jonathan J, Crockett, Matthew, Green, Jes, Bell, Lawrence TO, Hicks, Victoria, Crawford-Smith, Hugh, Morss, Amanda, Poulton, Lucinda, Pellisery, Bilgy, Hayes, Mark, Ludeman, Linmarie, Beasley, Matthew, Fulmali, Rahul, Anniss, Mark, Barnes, Elizabeth, Foy, Christopher, Nayar, Richard C, McMeekin, Faith, Gilbert, Hugh, Okeke, Aloysius |
| Zdroj: |
Journal of Clinical Urology; Jan2023, Vol. 16 Issue 1, p39-47, 9p |
| Abstrakt: |
Objectives: This study aimed to compare Likert scores with radical prostatectomy specimens. Methods: This study examined 443 men with validated pre-biopsy magnetic resonance imaging results and used cross-tabulation and chi-square significance testing with National Comprehensive Cancer Network risk categories. Results: The mean prostate-specific antigen (PSA) was 10, and the mean age was 64 years. Comparing Likert III to Likert V and Likert IV to Likert V, both (each p =0.02) were significantly associated with higher prostate cancer risk groups, but Likert III versus Likert IV was not (p =0.1). Within the subgroup PSA density (PSAD) <0.15 (n =140), the correlation of Likert score and final pathological risk group was lost (p =0.5), but it was not lost within the subgroup PSAD >0.15 (n =281; p =0.045 III vs. IV only and p =0.055 overall). Within the subgroup age <60 (n =104), the correlation of Likert score and final pathological risk group was significant (p =0.006 for III vs. IV and p =0.04 overall), whereas within the subgroup age >60 (n =339) this significant difference was lost (p =0.34). Further subgroup analysis within Likert III (n =86) found that men <60 (n =22) had neither high-grade (G3 or G4 or G5) nor very high-risk disease. There were only two high-risk cases, both of which were G2T3a (2/22; 10%). In men with Likert III and PSAD <0.15 (n =31), there were seven high-risk and two very high-risk cases (9/31; 25%). This difference was not significant (p =0.31) Conclusion: With these two findings, we recommend that men <60 with Likert III can be counselled like men with Likert III and PSAD <0.15, that they are unlikely to have unfavourable or high-risk disease and that they may wish to avoid biopsy or treatment. Level of evidence: Level 1b. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
